AKORN INC
BiotechAKORN INC is a biotechnology company focused on Cardiovascular, Neurology, Immunology.
AKORN INC's Key Drugs
AKORN INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AKORN INC's Recent FDA Approvals
New NDA/BLA approvals for AKORN INC over the last two years — novel drugs only, excluding generics and label supplements.
AKORN INC's Therapeutic Areas
AKORN INC's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AKORN INC's Top Competitors
AKORN INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AKORN INC Pipeline Snapshot
AKORN INC has 2 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2005-10-25
- Latest
- 2015-11-05
- Applications
- 3